Medicinova (MNOV) FCF Margin (2012 - 2025)

Medicinova (MNOV) posted quarterly FCF Margin of 1329.12% for Q4 2025, up 3.77% quarter-over-quarter from 1381.13% in Q3 2025.

Medicinova (MNOV) FCF Margin (2012 - 2025) Analysis & Trends

Medicinova (MNOV) has reported FCF Margin for 5 consecutive years, with 1329.12% the latest figure, recorded in Q4 2025.

In Q4 2025, FCF Margin changed N/A year-over-year to 1329.12%; the TTM figure through Dec 2025 stood at 2394.7% (changed N/A YoY), while the FY2025 annual figure was 2395.41%, changed N/A from the prior year.
FCF Margin rose to 1329.12% in Q4 2025 per MNOV's latest filing, from 1381.13% in the prior quarter.
Across five years, FCF Margin topped out at 96.35% in Q1 2021 and bottomed at 8049.5% in Q3 2021.
Historically, FCF Margin has averaged 2117.84% across 3 years, with a median of 1355.13% in 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	13.35%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	22.62%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-22.35%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	70.82%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	41.07%
10	Medicinova	66.94 Mn	66.94 Mn	317,759.00	-

Download Data